FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $42.5 million versus the consensus estimate of $49.77 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.